Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases

Trial Profile

Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Conbercept (Primary)
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 28 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top